BrightGene Fine Chemical Co., Ltd. (Tongyuan Road)
BrightGene Fine Chemical Co., Ltd. (Tongyuan Road) is a drug establishment in Taizhou, China, registered with the US FDA under FEI 3011254184. Its registered operations are: Analytical testing, API manufacture. 5 EU/UK GMP certificates are matched to this site, 2 inspected within the last three years; 1 has since been withdrawn by the issuing authority. FDA has published 2 inspection outcomes for this FEI; the most recent, ended 20 Jan 2024, was classified voluntary action indicated (VAI).
Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology
Cite as: PharmaTek, “BrightGene Fine Chemical Co., Ltd. (Tongyuan Road): FDA registration, inspection and GMP record (FEI 3011254184)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/brightgene-fine-chemical-co-ltd-tongyuan-road-taizhou-3011254184
Registered operations
Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.
GMP documents matched to this site (5)
| Document | Authority | Inspection | Source |
|---|---|---|---|
IT/E/API/08/2025 GMP certificate | Competent authority of Italy | 26 Apr 2025 within 3-year review window | EudraGMDP |
DE_TH_01H_GMP_2025_0020 GMP certificate | Competent authority of Germany | 13 Dec 2024 within 3-year review window | EudraGMDP |
DE_HH_01_GMP_2024_0014 GMP certificate | Competent authority of Germany | 28 Sept 2023 Superseded by a newer certificate; withdrawn on 3 Apr 2024 Register note: GMP certificate has been superseded by document with the number DE_HH_01_GMP_2024_0017 | EudraGMDP |
DE_HH_01_GMP_2024_0017 GMP certificate | Competent authority of Germany | 28 Sept 2023 outside 3-year review window | EudraGMDP |
DE_HE_01_GMP_2023_0223 GMP certificate | Competent authority of Germany | 25 Aug 2023 outside 3-year review window | EudraGMDP |
A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.
FDA inspection outcomes (2)
| Inspection ended | Outcome | Programme area | Citations posted |
|---|---|---|---|
| 20 Jan 2024 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
| 25 Sept 2015 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection. FDA firm profile
What this page does not show
- Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
- Capacity, scale, price or current availability: no regulator publishes these.
- The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
Other sites registered by the same company
Is this BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.